Imaging kidney biopsies with optical coherence tomography for kidney disease diagnosis

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with suspected acute kidney injury or suspected chronic kidney disease who need a kidney biopsy in the nephrology department.

Age

Over 18 years

Sex

All sexes

Disease stage

Suspected acute kidney injury or suspected chronic kidney disease that needs a biopsy.

Main reasons for not taking part

• Cannot have the dynamic full-field optical coherence tomography observation at the time of the kidney biopsy

The registry criteria, word for word

What the trial wants to find out

Kidney biopsy play a key role for the investigation of either acute kidney injury or chronic kidney disease. Despite possible complications due to the invasive nature of the biopsy, such procedure is still essential in a number of clinical situations to improve the diagnosis specificity of kidney disease, better inform about its prognosis and guide the management of a future treatment. Pursuing the idea to improve both performance and rapidity associated with the histopathological analysis of kidney biopsy, with a possible recourse to artificial intelligence-based renal pathology, the present study intends to assess the impact of direct histopathological examination of kidney biopsy with dynamic full-field optical coherence tomography in routine practices for the diagnosis of either acute kidney injury or chronic kidney disease.

The group in the trial

• NEPHROCT cohort

  Patients \> 18 years of age with suspected acute kidney injury or chronic kidney disease requiring biopsy in the nephrology department

  Treatment: Dynamic full-field optical coherence tomography analysis of kidney biopsy